- Home
- LRE vs INDP Comparison
LRE vs INDP Comparison
Compare LRE & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRE
- INDP
- Stock Information
- Founded
- LRE 2001
- INDP 2000
- Country
- LRE Japan
- INDP United States
- Employees
- LRE N/A
- INDP N/A
- Industry
- LRE
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- LRE
- INDP Health Care
- Exchange
- LRE Nasdaq
- INDP Nasdaq
- Market Cap
- LRE 19.2M
- INDP 15.4M
- IPO Year
- LRE 2023
- INDP N/A
- Fundamental
- Price
- LRE $1.51
- INDP $1.16
- Analyst Decision
- LRE
- INDP Strong Buy
- Analyst Count
- LRE 0
- INDP 1
- Target Price
- LRE N/A
- INDP $12.00
- AVG Volume (30 Days)
- LRE 7.4K
- INDP 21.1K
- Earning Date
- LRE 01-01-0001
- INDP 11-04-2024
- Dividend Yield
- LRE N/A
- INDP N/A
- EPS Growth
- LRE N/A
- INDP N/A
- EPS
- LRE 0.25
- INDP N/A
- Revenue
- LRE $118,414,146.00
- INDP N/A
- Revenue This Year
- LRE N/A
- INDP N/A
- Revenue Next Year
- LRE N/A
- INDP N/A
- P/E Ratio
- LRE $6.00
- INDP N/A
- Revenue Growth
- LRE 14.65
- INDP N/A
- 52 Week Low
- LRE $1.19
- INDP $1.03
- 52 Week High
- LRE $13.76
- INDP $3.25
- Technical
- Relative Strength Index (RSI)
- LRE 48.23
- INDP 36.05
- Support Level
- LRE $1.51
- INDP $1.11
- Resistance Level
- LRE $1.63
- INDP $1.27
- Average True Range (ATR)
- LRE 0.10
- INDP 0.13
- MACD
- LRE 0.03
- INDP -0.00
- Stochastic Oscillator
- LRE 65.79
- INDP 22.03
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo and Kanagawa prefecture. It operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. It generates revenue from developing and selling single-family homes and condominiums. The company's primary and sole operating segment is real estate sales.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.